Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:
Karen Anjema Declared that the work presented was founded by a research grant of Merck, The Netherlands.
Amaya Bélanger-Quintana Declared receipt of honoraria or consultation fees from Mead Johnson and to be member of Merck Serono advisory board. Declared that her presentation will discuss current off-label but approved use of sapropterin as compassionate medication.
Nenad Blau Declared to be a member of MerckSerono SA. Switzerland PKU advisory board.
Annet M. Bosch Declared to be member of Merck Serono advisory board on development of a QoL questionnaire for PKU and of the Advisory board ELEMENT committee of Nutricia.
Sandra D. Arduim Brasil Declared no potential conflict of interest.
Alberto Burlina Declared to be member of KAMPER advisory board.
Martijn de Groot Declared that her work was funded by a research grant of Merck-the Netherlands.
Mübeccel Demirkol Declared to be member of Scientific Board of European PKU Group.
Lourdes Ruiz Desviat Declared no potential conflict of interest.
François Feillet Declared to be member of the advisory board of Merck Serono on PKU, member of the advisory board of the KAMPER registry and member of the advisory board of Nutricia on nutritional treatment of IEM.
Marcello Giovannini Declared to be member of Merck Serono advisory board – European PKU Group (SAB / EPG).
Maria Giżewska Declared receipt of honoraria or consultation fees from Nutricia Advanced Medical Nutrition for preparing educational materials for patients and professionals and to be member of Experts Leading Education in Metabolic Error Nutritional Therapy (ELEMENT), Nutricia Advanced Medical Nutrition. Declared also to have been speaker for Nutricia Advanced Medical Nutrition and Merck and invited guest for Merck “Luminaries meeting” Geneva 18-19 November 2010.
Cary O. Harding Declared receipt of contracts for clinical research with BioMarin Corp. and SHS Nutricia and receipt of honoraria for participation in BioMarin scientific workshops.
Julia B. Hennermann Declared to have participated in the KAMPER study and in the PKU – 001 - 008 studies.
Stephan Huijbregts Declared receipt of grants and contracts from NutsOhra Research Funding: Executive Function in Adolescents and Young Adults with PKU: A Follow-up Study after 10 years (with Dr. Van Spronsen and Dr. De Sonneville). Declared also receipt of honoraria and consultation fees as Consultant/Member of Steering Committee of Merck Serono S.A., Geneva, Switzerland – “A Multicenter, Double-Blind, Placebo-Controlled, Randomized, 2-Arm Phase IIIb Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults in Phenylketonuria” (SIGNAL).
Patrícia Janeiro Declared no potential conflict of interest.
Ulrich Langenbeck Declared no potential conflict of interest.
João Travassos Leandro Declared that the investigational status of products used in in vitro studies will be clearly stated in the slides and presentation.
Vincenzo Leuzzi Declared no potential conflict of interest.
Uta Lichter-Konecki Declared receipt of grants and contracts to participate in the BIOMARIN PKU Registry which documents clinical data of patients on KUVAN and to be conducting clinical trials with Hyperion and Cytonet in patients with urea cycle disorders and to receive a reimbursement for the efforts of conducting the trials.
Anita MacDonald Declared receipt of research grant/posts from Nutricia and Vitaflo, of honoraria from Nutricia, Vitaflo and Merck Serono, member of Sapropterin PKU Advisory Board; Chair of ENEP; and Member of Nutricia Advisory Board for IMD.
François Maillot Declared no potential conflict of interest.
Aurora Martinez Declared that her presentation will include among other results with some compounds discovered by high throughput screening, already published in: Pey AL, Ying M, Cremades N, Velazquez-Campoy A, Scherer T, Thöny B, Sancho J and Martinez A (2008). Pharmacological chaperones as therapeutic agents to treat phenylketonuria. J. Clin. Invest. 118, 2858-2867
Kristina Motzfeldt Declared to be Member of ENEP, European Nutritional Expert Panel in PKU, sponsored by Merck Serono and that she will be sponsored by SHS International for travelling expenses to a meeting in Metabolic in April 2011 in London.
Ania Muntau Declared receipt of grants and contracts, honoraria or consultation fees from Merck Serono and to be member of Merck Serono advisory board.
Isabel Antolin Rivera Declared no potential conflict of interest.
Júlio César Rocha Declared participation at the Merck Serono’s Satellite Symposium – SSIEM 2010 and to be member of the European Nutritionist Expert Panel – Merck Serono
Rani H. Singh Declared receipt of contract with BioMarin and that her presentation will report investigator-sponsored trial results sponsored by US the company, BioMarin.
Martin Schwarz Declared no potential conflict of interest.
Isabel Tavares de Almeida Declared no potential conflict of interest.
Friedrich K. Trefz Declared to be member of the European PKU Advisory Board.
Kurt Ullrich Declared no potential conflict of interest.
Margreet van Rijn Declared receipt of honoraria or consultation fees as member of the ENEP Nutritionist expert panel.
Carmen Regla Vargas Declared no potential conflict of interest.
Hiu Man Viecelli Declared no potential conflict of interest.
MªAntonia Vilaseca Declared no potential conflict of interest.
John Walter Declared no potential conflict of interest.
The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of March 10, 2011.
Iris Scala
Francjan J. van Spronsen